Success Metrics

Clinical Success Rate

85.7%

Based on 60 completed trials

Completion Rate

86%(60/70)

Active Trials

6(6%)

Results Posted

90%(54 trials)

Terminated

10(10%)

Phase Distribution

Ph not_applicable

Ph phase_2

20%

Ph early_phase_1

Ph phase_1

Ph phase_3

34%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution89 total trials

Early Phase 1First-in-human

3(3.4%)

Phase 1Safety & dosage

5(5.6%)

Phase 2Efficacy & side effects

20(22.5%)

Phase 3Large-scale testing

34(38.2%)

Phase 4Post-market surveillance

25(28.1%)

N/ANon-phased studies

2(2.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.2%

60 of 73 finished

Non-Completion Rate

17.8%

13 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(60)

Terminated(13)

Other(18)

Detailed Status

Completed60

unknown18

Terminated10

Recruiting4

Withdrawn3

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (3.4%)

Phase 15 (5.6%)

Phase 220 (22.5%)

Phase 334 (38.2%)

Phase 425 (28.1%)

N/A2 (2.2%)

Trials by Status

active_not_recruiting22%

not_yet_recruiting22%

terminated1010%

unknown1818%

withdrawn33%

completed6061%

recruiting44%

Recent Activity

6 active trials

Showing 5 of 99

terminatedphase_2

YN001-004 in Patients With Coronary Atherosclerosis in Australia

NCT06700720

not_yet_recruitingphase_4

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

NCT07803679

active_not_recruitingphase_2

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

NCT06284564

completedphase_3

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

NCT03872401

recruitingphase_4

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

NCT07612774

View all 99 trials

Clinical Trials (99)

Showing 20 of 99 trialsScroll for more

NCT06700720Phase 2

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Terminated

NCT07803679Phase 4

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

Not Yet Recruiting

NCT06284564Phase 2

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Active Not Recruiting

NCT03872401Phase 3

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Completed

NCT07612774Phase 4

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Recruiting

NCT03337698Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Terminated

NCT05144529Phase 2

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Terminated

NCT03515304Phase 2

Evolocumab in Acute Coronary Syndrome

Completed

NCT03829046Phase 4

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Completed

NCT06081153Early Phase 1

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA